m****e
发帖数: 489 | | B**********r
发帖数: 267 | 2 股版生拉投机客血本无归
【在 m****e 的大作中提到】
: 哭死！！
| m****e
发帖数: 489 | 3 怎么办啊？割肉的话也太痛了！ 缩水了这么多，什么时候能涨上去啊？？ | a*****h
发帖数: 7463 | 4 为什么动这些小医药股？
【在 m****e 的大作中提到】
: 哭死！！
| S*P
发帖数: 7575 | 5 Stimuvax, which Merck licensed from U.S. biotech firm Oncothyreon, failed to
increase overall survival in the Phase III clinical trial, the German
chemicals and pharmaceuticals group said on Wednesday.
The trial's coordinating investigator, Frances Shepherd of the University of
Toronto, said the result was disappointing, although she said "notable
treatment effects were observed in certain subgroups of patients".
While this could mean that Merck might conduct more studies to try and find
particular groups of patients who would benefit from the treatment, industry
analysts were sceptical that Stimuvax had any future.
"Despite potential positive effects in subgroups, we consider the drug dead,
" said Deutsche Bank analyst Holger Blum.
The trial was testing Stimuvax on more than 1,500 patients with stage III
non-small cell lung cancer whose tumours could not be completely removed via
surgery and whose disease had at least stabilised following
chemoradiotherapy. |
|
